Fifteen-foot diameter modular space station Kennedy Space Center launch site support definition (space station program Phase B extension definition)

This document defines the facilities, equipment, and operational plans required to support the MSS Program at KSC. Included is an analysis of KSC operations, a definition of flow plans, facility utilization and modifications, test plans and concepts, activation, and tradeoff studies. Existing GSE and facilities that have a potential utilization are identified, and new items are defined where possible. The study concludes that the existing facilities are suitable for use in the space station program without major modification from the Saturn-Apollo configuration

Ultra Wideband for Shipyard 5.0 Indoor Gantry Crane High-Precision Positioning

Cursos e Congresos, C-155[Abstract] The shipyard of the future, called Shipyard 5.0, is a highly technological environment where real-time monitoring of products, by-products and transport vehicles is crucial. Among the technologies able to locate such elements indoors, Ultra Wideband (UWB) is a good option for providing accurate positioning. However, the use of UWB in shipyards faces challenges due to interference from metallic objects, which impacts its accuracy. To validate the use of UWB in a shipyard, this paper presents tests that were carried out in workshops that Navantia owns in Ferrol’s estuary, where UWB tags were placed on a gantry crane hook. The presented results show the performance of the system when locating the hook in 3D and the impact of attaching multiple tags to the hook to harness signal diversity. Specifically, a relatively lowerror is obtained when estimating only the height of the gantry crane hook (approximately 1 m), while the threedimensional positioning error reached an error of between 2 and 3m for the z-axisXunta de Galicia; IN853C 2022/01Xunta de Galicia; ED431C 2020/15This work has been funded by CITIC that is funded by the Xunta de Galicia through the collaboration agreement between the Consellería de Cultura, Educación, Formación Profesional e Universidades and the Galician universities for the reinforcement of the research centres of the Galician University System (CIGUS), by the Xunta de Galicia (by grant ED431C 2020/15), and by grant PID2020-118857RA-100 (ORBALLO) funded by MCIN/AEI/10.13039/501100011033. In addition, this work has been supported by Xunta de Galicia through Axencia Galega de Innovación (GAIN) by grant IN853C 2022/01, Centro Mixto de Investigaci ón UDC-NAVANTIA “O estaleiro do futuro”, which is ongoing until the end of September 2025. The support was inherited from both the starting and consolidation stages of the same project throughout 2015- 2018 and 2018-2021, respectively. This stage is also co-funded by ERDF funds from the EU in the framework of program FEDER Galicia 2021-202

A Bluetooth 5 Opportunistic Edge Computing System for Vehicular Scenarios

[Abstract]: The limitations of many IoT devices in terms of storage, computing power and energy consumption require them to be connected to other devices when performing computationally intensive tasks, as happens with IoT systems based on edge computing architectures. However, the lack of wireless connectivity in the places where IoT nodes are deployed or through which they move is still a problem. One of the solutions to mitigate this problem involves using opportunistic networks, which provide connectivity and processing resources efficiently while reducing the communications traffic with remote clouds. Thus, opportunistic networks are helpful in situations when wireless communication coverage is not available, as occurs in certain rural areas, during natural disasters, in wars or when other factors cause network disruptions, as well as in other IoT scenarios in which the cloud becomes saturated (for example, due to an excessive amount of concurrent communications or when denial-of-service (DoS) attacks occur). This article presents the design and initial validation of a novel opportunistic edge computing (OEC) system based on Bluetooth 5 and the use of low-cost single-board computers (SBCs). After describing the proposed OEC system, experimental results are presented for a real opportunistic vehicular IoT scenario. Specifically, the latency and packet loss are measured thanks to the use of an experimental testbed made of two separate IoT networks (each conformed by an IoT node and an OEC gateway): one located in a remote office and another one inside a moving vehicle, which was driven at different vehicular speeds. The obtained results show average latencies ranging from 716 to 955 ms with packet losses between 7% and 27%. As a result, the developed system is useful for providing opportunistic services to moving IoT nodes with relatively low latency requirements.Xunta de Galicia; ED431C 2020/15Xunta de Galicia; ED431G 2019/01Ministerio de Ciencia e Innovación; PID2020-118857RA-I0

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD

Altres ajuts: Boehringer IngelheimAltres ajuts: European Respiratory Society (ERS)Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD; however, a significant proportion of patients at low risk of exacerbations are treated with ICSs. We conducted a systematic review including a diversity of types of study designs and safety outcomes with the objective of describing the risk of adverse effects associated with the long-term use of ICSs in patients with COPD. A total of 90 references corresponding to 83 studies were included, including 26 randomised clinical trials (RCTs), 33 cohort studies, and 24 nested case-control (NCC) studies. Analysis of 19 RCTs showed that exposure to ICSs for ⩾1 year increased the risk of pneumonia by 41% (risk ratio 1.41, 95% CI 1.23-1.61). Additionally, cohort and NCC studies showed an association between ICSs and risk of tuberculosis and mycobacterial disease. There was a strong association between ICS use and local disorders such as oral candidiasis and dysphonia. The association between ICSs and the risk of diabetes and fractures was less clear and appeared significant only at high doses of ICSs. Since most patients with COPD are elderly and with frequent comorbidities, an adequate risk-benefit balance is crucial for the indication of ICSs

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD

MPOC; TabaquismeEPOC; TabaquismoCOPD; SmokingInhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD; however, a significant proportion of patients at low risk of exacerbations are treated with ICSs. We conducted a systematic review including a diversity of types of study designs and safety outcomes with the objective of describing the risk of adverse effects associated with the long-term use of ICSs in patients with COPD. A total of 90 references corresponding to 83 studies were included, including 26 randomised clinical trials (RCTs), 33 cohort studies, and 24 nested case–control (NCC) studies. Analysis of 19 RCTs showed that exposure to ICSs for ≥1 year increased the risk of pneumonia by 41% (risk ratio 1.41, 95% CI 1.23–1.61). Additionally, cohort and NCC studies showed an association between ICSs and risk of tuberculosis and mycobacterial disease. There was a strong association between ICS use and local disorders such as oral candidiasis and dysphonia. The association between ICSs and the risk of diabetes and fractures was less clear and appeared significant only at high doses of ICSs. Since most patients with COPD are elderly and with frequent comorbidities, an adequate risk–benefit balance is crucial for the indication of ICSs.This study was funded by an unrestricted grant from Boehringer Ingelheim

Protocolo de sedo-analgesia para prevención del espasmo radial en hemodinámica cardíaca

Introducción y objetivo: El espasmo es la complicación más habitual en los cateterismos por arteria radial. Su frecuencia oscila entre el 10-30% y puede ser un factor limitante que impida la realización del cateterismo por esa vía. El objetivo de este estudio es evaluar con un nuevo protocolo de sedo-analgesia la reducción de la frecuencia del espasmo radial y la disminución de la ansiedad del paciente. Material y método: Estudio aleatorizado y prospectivo de 300 pacientes sometidos a cateterismo radial. Se randomizaron dos grupos, el Grupo I (n=150) con la pauta de sedación habitual (10mg diazepam sl) y el Grupo II (n=150) con una pauta de sedación con 2 mg de Midazolam + 0,035 mg/kg de Cloruro Mórfico y en caso de procedimientos de más de 45 minutos se añadía Fentanilo a 1 mcgr/kg. Resultados y conclusión: No se observaron diferencias significativas entre los dos grupos estudiados en cuanto a las características basales. La edad media de la población fue de 65 ± 11 años; 223 pacientes (74%) fueron hombres y el índice de masa corporal (IMC) medio 27,7 ± 3,8. Los pacientes del Grupo II presentaron reducción significativa del espasmo respecto a los del Grupo I (9,3% frente a 22,6%; p=0,002). También se objetivó una reducción significativa del dolor (2,05 frente a 2,77; p=0,007). La pauta sedo-analgésica propuesta demostró ser eficaz en la reducción del espasmo radial y del dolor durante el cateterismo

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Ibrutinib; Mantle cell lymphomaIbrutinib; Linfoma de células del mantoIbrutinib; Limfoma de cèl·lules de mantellPURPOSE The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients. METHODS This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m2. Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria. RESULTS Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia. CONCLUSION Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases.The funding for the IMCL-2015 was obtained through unrestricted Janssen Clinical Investigator-Initiated Study (IIS) Research Support

HIMENOLEPIASIS EN ESCOLARES DE CIUDAD BOLIVAR, ESTADO BOLIVAR, VENEZUELA

Con el propósito de determinar la prevalencia de Hymenolepis nana y estudiar las manifestaciones clínicas de la Himenolepiasis, se evaluaron 422 escolares de ambos sexos entre 6 y 12 años. En el estudio coproparasitológico se utilizaron la técnica de examen directo y el método de flotación en salmuera (Willis). Se determinó una prevalencia de 3,55% ± 1,62%. No se observaron diferencias significativas al evaluar la relación con sexo (P > 0,05) y edad (x2 - 3,95; g.l.- 6). En 11 casos (73,33%) se identificó otro parásito asociado. El cestodo se encontró como parásito único en 4 (26.67%) niños. De los 15 escolares con H. nana, 9 (60%) presentaban algunas manifestaciones clínicas, siendo las digestivas y generales, más frecuentes: diarrea (5 casos), pérdida de peso (4 casos). Cefalea, hiporexia y dermatitis fueron otras manifestaciones importantes. Se concluye que H. nana presenta una prevalencia baja en escolares de Ciudad Bolívar y debe tenerse un alto índice de sospecha clínica pues el40% de los casos son asintomáticos.   PALABRAS CLAVES: Hymenolepis nana, himenolepiasis, prevalencia, manifestaciones clínicas, escolares.   ABSTRACT   In order to determine the prevalence of Himenolepsis nana and to study its clinical manifestations, we evaluated 422 schoolchildren of both sexes, between 6 and 12 years old. The coproparasitological study was made by using both direct examination of feces and the brine flotation method (Willis). A prevalence of 3,55% ± 1,61 % was observed. No significant differences appeared in relation with sex {P>0,05) or age (X2 = 3,95; g.l. = 6). In 11 cases (73,33% ), we identified another associated parasite. Cestodes were found as unique parsites in 4 (26 .67 %) children. Among the 15 schoolchildren infected by H. nana, 9 of tl1em showed any clinical manifestations. The most frequent of these ware digestive and general: diarrhea (5 cases) and weight loss (4 cases). Headaches, hyporexia and dermatitis were others. We conclude that H. nana shows low prevalence in schoolchildren from Ciudad Bolívar, but that one should maintain a high degree of clinical suspicion, as 40% of the cases are asymptomat.ic.   KEY WORDS: Hymenolepis nana, himenolepiasis, prevalence, clinical manifestations, school children

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

N

Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

Síndrome de Sézary; Coste de la enfermedad; FarmacoeconomíaSézary syndrome; Cost of disease; PharmacoeconomicsSíndrome de Sézary; Cost de la malaltia; FarmacoeconomiaAntecedentes y objetivo No se dispone de datos españoles sobre el coste asociado al linfoma cutáneo de células T (LCCT). Además, la incorporación de nuevos tratamientos hace necesario analizar el coste real de la enfermedad. El estudio MICADOS analizó dos objetivos principales: Por un lado, evaluó el impacto en la calidad de vida en los pacientes con LCCT, y por otro lado, estudió los costes de la enfermedad. En esta publicación se recoge el segundo de los objetivos del estudio. Métodos El coste de la enfermedad se estudió bajo la perspectiva del Sistema Nacional de Salud (SNS) con un horizonte temporal de un año. Participaron 23 dermatólogos y hematólogos de 15 hospitales públicos españoles. Se incluyeron pacientes adultos con LCCT del tipo micosis fungoide (MF) y síndrome de Sézary (SS). Resultados Se incluyeron 141 pacientes, el 57,4% masculinos, con una edad media de 63,6 años (IC 95%: 61,4-65,7). Los costes directos anuales medios por pacientes del estudio fueron de 34.214€, siendo de 11.952,47€ en estadio I, 23.506,21€ en estadio II, 38.771,81€ en estadio III y 72.748,84€ en estadio IV. El coste anual directo total estimado de todos los pacientes en España con MF/SS resultó en 78.301.171€, donde el 81% de los costes fueron atribuibles a pacientes en estadio I, el 7% al estadio II, el 6% al estadio III y el 6% al estadio IV. Conclusiones Este estudio ofrece una evaluación precisa del coste directo del LCCT en pacientes con MF/SS en España, mostrando costes que varían sustancialmente en función del estadio. Los costes soportados por el paciente y los costes indirectos deberán considerarse en futuras investigaciones.Background and objective The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1) to evaluate the impact of CTCL on patient quality of life, and 2) to evaluate the costs associated with the disease. This article reports the results of the cost analysis. Methods We estimated the cost of treating CTCL over a period of 1 year from the perspective of the Spanish National Health System. Twenty-three dermatologists and hematologists from 15 public hospitals analyzed data for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS). Results A total of 141 patients (57.4% male) with a mean age of 63.6 years (95% CI: 61.4-65.7 years) were included. The mean direct annual cost of treating CTCL was €34,214 per patient. The corresponding costs by stage were €11,952.47 for stage I disease, €23,506.21 for stage II disease, €38,771.81 for stage III disease, and €72,748.84 for stage IV disease. The total direct annual cost of treating MF/SS in public hospitals in Spain was estimated at €78,301,171; stage I disease accounted for 81% of all costs, stage II for 7%, and stages III and IV for 6% each. Conclusions The MICADOS study offers an accurate picture of the direct cost of treating CTCL in patients with MF/SS in Spain and shows that costs vary significantly according to disease stage. Patient-borne and indirect costs should be analyzed in future studies.El estudio fue financiado en su totalidad por Kyowa Kirin Farmacéutica, S.L